# Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers

> **NCT03868072** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 40 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** XELJANZ 5Mg Tablet
- **DRUG:** Chong Kun Dang Tofacitinib Tablet

## Key facts

- **NCT ID:** NCT03868072
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-22
- **Primary completion:** 2019-03-29
- **Final completion:** 2019-04-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03868072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03868072, "Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03868072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*